25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

Bioventus Inc
Buy, Hold or Sell?

Let's analyze Bioventus together

I guess you are interested in Bioventus Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Bioventus Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Bioventus Inc

I send you an email if I find something interesting about Bioventus Inc.

1. Quick Overview

1.1. Quick analysis of Bioventus (30 sec.)










1.2. What can you expect buying and holding a share of Bioventus? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
40.9%

What is your share worth?

Current worth
$2.86
Expected worth in 1 year
$2.25
How sure are you?
40.9%

+ What do you gain per year?

Total Gains per Share
$-0.61
Return On Investment
-6.0%

For what price can you sell your share?

Current Price per Share
$10.11
Expected price per share
$5.28 - $10.94
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Bioventus (5 min.)




Live pricePrice per Share (EOD)
$10.11
Intrinsic Value Per Share
$1.53 - $1.82
Total Value Per Share
$4.39 - $4.68

2.2. Growth of Bioventus (5 min.)




Is Bioventus growing?

Current yearPrevious yearGrowGrow %
How rich?$186.8m$260.1m-$56.5m-27.8%

How much money is Bioventus making?

Current yearPrevious yearGrowGrow %
Making money-$9.8m-$38.9m$29m294.8%
Net Profit Margin-6.8%-32.1%--

How much money comes from the company's main activities?

2.3. Financial Health of Bioventus (5 min.)




2.4. Comparing to competitors in the Medical Devices industry (5 min.)




  Industry Rankings (Medical Devices)  


Richest
#100 / 312

Most Revenue
#72 / 312

Most Profit
#239 / 312

Most Efficient
#142 / 312
3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Bioventus?

Welcome investor! Bioventus's management wants to use your money to grow the business. In return you get a share of Bioventus.

First you should know what it really means to hold a share of Bioventus. And how you can make/lose money.

Speculation

The Price per Share of Bioventus is $10.11. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Bioventus.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Bioventus, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $2.86. Based on the TTM, the Book Value Change Per Share is $-0.15 per quarter. Based on the YOY, the Book Value Change Per Share is $-1.15 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Bioventus.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.07-0.7%-0.15-1.5%-1.11-10.9%-0.24-2.4%-0.24-2.4%
Usd Book Value Change Per Share-0.03-0.3%-0.15-1.5%-1.15-11.4%0.000.0%0.131.3%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.020.2%0.020.2%
Usd Total Gains Per Share-0.03-0.3%-0.15-1.5%-1.15-11.4%0.020.2%0.151.5%
Usd Price Per Share11.95-7.04-2.47-6.37-5.80-
Price to Earnings Ratio-40.48--19.28--5.16--49.73--45.21-
Price-to-Total Gains Ratio-350.45--130.11--14.96--138.14--138.14-
Price to Book Ratio4.18-2.32-0.64-1.55-1.40-
Price-to-Total Gains Ratio-350.45--130.11--14.96--138.14--138.14-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share10.11
Number of shares98
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.02
Usd Book Value Change Per Share-0.150.00
Usd Total Gains Per Share-0.150.02
Gains per Quarter (98 shares)-14.852.35
Gains per Year (98 shares)-59.409.40
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-59-6990-1
20-119-1281808
30-178-18728017
40-238-24637126
50-297-30546135
60-356-36455144
70-416-42365153
80-475-48274162
90-535-54183171
100-594-60092280

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%1.011.00.08.3%6.014.00.030.0%6.016.00.027.3%6.016.00.027.3%
Book Value Change Per Share0.04.00.00.0%2.010.00.016.7%4.014.02.020.0%5.014.03.022.7%5.014.03.022.7%
Dividend per Share0.00.04.00.0%1.00.011.08.3%9.00.011.045.0%9.00.013.040.9%9.00.013.040.9%
Total Gains per Share0.04.00.00.0%2.010.00.016.7%8.012.00.040.0%9.012.01.040.9%9.012.01.040.9%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Bioventus Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.034-0.152+344%-1.153+3282%0.000-8495%0.130-126%
Book Value Per Share--2.8583.115-8%3.979-28%4.096-30%3.853-26%
Current Ratio--1.4121.452-3%1.369+3%1.360+4%1.289+10%
Debt To Asset Ratio--0.7570.743+2%0.731+4%0.685+10%0.651+16%
Debt To Equity Ratio--3.9173.670+7%3.320+18%2.763+42%2.585+52%
Dividend Per Share----0%-0%0.024-100%0.021-100%
Enterprise Value--241560210.000-93438018.500+139%-521828953.500+316%-34363945.200+114%-34363945.200+114%
Eps---0.074-0.151+105%-1.106+1399%-0.243+229%-0.240+225%
Ev To Ebitda Ratio--3.558-0.036+101%9.365-62%4.364-18%4.364-18%
Ev To Sales Ratio--0.435-0.170+139%-1.043+340%0.023+1804%0.023+1804%
Free Cash Flow Per Share--0.1570.104+51%-0.001+100%0.067+135%0.055+187%
Free Cash Flow To Equity Per Share--0.1620.063+156%-0.123+176%0.273-40%0.249-35%
Gross Profit Margin--1.0001.158-14%1.029-3%1.037-4%1.034-3%
Intrinsic Value_10Y_max--1.823--------
Intrinsic Value_10Y_min--1.532--------
Intrinsic Value_1Y_max--0.072--------
Intrinsic Value_1Y_min--0.071--------
Intrinsic Value_3Y_max--0.300--------
Intrinsic Value_3Y_min--0.285--------
Intrinsic Value_5Y_max--0.631--------
Intrinsic Value_5Y_min--0.578--------
Market Cap660868458.000-18%781145210.000460352731.500+70%161295046.500+384%416687041.100+87%378806401.000+106%
Net Profit Margin---0.035-0.068+97%-0.321+825%-0.062+78%-0.078+126%
Operating Margin--0.034-0.026+177%0.151-78%0.058-42%0.047-28%
Operating Ratio--0.9380.955-2%1.039-10%0.979-4%0.987-5%
Pb Ratio3.537-18%4.1812.323+80%0.639+555%1.545+171%1.405+198%
Pe Ratio-34.249+15%-40.482-19.280-52%-5.162-87%-49.732+23%-45.211+12%
Price Per Share10.110-18%11.9507.043+70%2.468+384%6.375+87%5.795+106%
Price To Free Cash Flow Ratio16.116-18%19.0495.876+224%1.660+1047%7.487+154%6.807+180%
Price To Total Gains Ratio-296.487+15%-350.446-130.112-63%-14.962-96%-138.141-61%-138.141-61%
Quick Ratio--0.7800.823-5%0.775+1%0.934-16%0.879-11%
Return On Assets---0.006-0.012+99%-0.040+533%-0.007+19%-0.007+17%
Return On Equity---0.032-0.063+95%-0.183+465%-0.037+14%-0.035+8%
Total Gains Per Share---0.034-0.152+344%-1.153+3282%0.024-242%0.151-123%
Usd Book Value--186833000.000203611250.000-8%260122750.000-28%267767250.000-30%251893045.455-26%
Usd Book Value Change Per Share---0.034-0.152+344%-1.153+3282%0.000-8495%0.130-126%
Usd Book Value Per Share--2.8583.115-8%3.979-28%4.096-30%3.853-26%
Usd Dividend Per Share----0%-0%0.024-100%0.021-100%
Usd Enterprise Value--241560210.000-93438018.500+139%-521828953.500+316%-34363945.200+114%-34363945.200+114%
Usd Eps---0.074-0.151+105%-1.106+1399%-0.243+229%-0.240+225%
Usd Free Cash Flow--10252000.0006789250.000+51%-45500.000+100%4365400.000+135%3577500.000+187%
Usd Free Cash Flow Per Share--0.1570.104+51%-0.001+100%0.067+135%0.055+187%
Usd Free Cash Flow To Equity Per Share--0.1620.063+156%-0.123+176%0.273-40%0.249-35%
Usd Market Cap660868458.000-18%781145210.000460352731.500+70%161295046.500+384%416687041.100+87%378806401.000+106%
Usd Price Per Share10.110-18%11.9507.043+70%2.468+384%6.375+87%5.795+106%
Usd Profit---4824000.000-9870500.000+105%-38968750.000+708%-8678950.000+80%-9120272.727+89%
Usd Revenue--138964000.000138765250.000+0%125689000.000+11%115106100.000+21%110040272.727+26%
Usd Total Gains Per Share---0.034-0.152+344%-1.153+3282%0.024-242%0.151-123%
 EOD+4 -4MRQTTM+26 -12YOY+26 -125Y+18 -2210Y+18 -22

3.3 Fundamental Score

Let's check the fundamental score of Bioventus Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-34.249
Price to Book Ratio (EOD)Between0-13.537
Net Profit Margin (MRQ)Greater than0-0.035
Operating Margin (MRQ)Greater than00.034
Quick Ratio (MRQ)Greater than10.780
Current Ratio (MRQ)Greater than11.412
Debt to Asset Ratio (MRQ)Less than10.757
Debt to Equity Ratio (MRQ)Less than13.917
Return on Equity (MRQ)Greater than0.15-0.032
Return on Assets (MRQ)Greater than0.05-0.006
Total3/10 (30.0%)

3.4 Technical Score

Let's check the technical score of Bioventus Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5046.575
Ma 20Greater thanMa 5010.205
Ma 50Greater thanMa 10011.063
Ma 100Greater thanMa 20011.321
OpenGreater thanClose9.740
Total1/5 (20.0%)

4. In-depth Analysis

4.1 About Bioventus Inc

Bioventus Inc., a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain. Its surgical solutions comprise bone graft substitutes that increase bone formation to stimulate bone healing in spinal fusions and other orthopedic surgeries; and ultrasonic products used for precise bone cutting and sculpting, soft tissue management, and tissue debridement, in various surgeries, including minimally invasive applications. The company's product include, Osteoamp, an allograft-derived bone graft for bone grafting procedures; Exponent matrix for posterolateral spine procedures; Purebone for bone grafting procedures; Signafuse bone graft; Interfuse bone graft; Osteomatrix+ synthetic bone graft; Extractor for autologous cell and bone marrow extraction; reficio bone matrix; nexus ultrasonic surgical system; bonescalpel surgical solution; SonaStar for surgical procedures; and SonicOne ultrasonic cleansing and debridement system. The company's restorative therapies include a bone stimulation system and devices to help patients regain leg or hand function due to stroke, multiple sclerosis, or other central nervous system disorders. Its products include exogen, a bone healing system; L300 GO, a foot drop system; H200 rehabilitation system; Vector, a body weight support system; and Bioness integrated therapy system. It developing Talisman pulse generator and receiver for peripheral nerve stimulation. The company was founded in 2011 and is headquartered in Durham, North Carolina.

Fundamental data was last updated by Penke on 2025-01-16 14:57:04.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is less efficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is just able to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is able to pay all its debts by selling its assets.
The company is unable to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is cheap.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profit Bioventus earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Bioventus to the Medical Devices industry mean.
  • A Net Profit Margin of -3.5% means that $-0.03 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Bioventus Inc:

  • The MRQ is -3.5%. The company is making a loss. -1
  • The TTM is -6.8%. The company is making a loss. -1
Trends
Current periodCompared to+/- 
MRQ-3.5%TTM-6.8%+3.4%
TTM-6.8%YOY-32.1%+25.3%
TTM-6.8%5Y-6.2%-0.6%
5Y-6.2%10Y-7.8%+1.6%
Compared to industry (Medical Devices)
PeriodCompanyIndustry (mean)+/- 
MRQ-3.5%-6.7%+3.2%
TTM-6.8%-14.2%+7.4%
YOY-32.1%-15.0%-17.1%
5Y-6.2%-15.7%+9.5%
10Y-7.8%-14.9%+7.1%
4.3.1.2. Return on Assets

Shows how efficient Bioventus is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Bioventus to the Medical Devices industry mean.
  • -0.6% Return on Assets means that Bioventus generated $-0.01 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Bioventus Inc:

  • The MRQ is -0.6%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -1.2%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-0.6%TTM-1.2%+0.6%
TTM-1.2%YOY-4.0%+2.7%
TTM-1.2%5Y-0.7%-0.5%
5Y-0.7%10Y-0.7%0.0%
Compared to industry (Medical Devices)
PeriodCompanyIndustry (mean)+/- 
MRQ-0.6%-2.8%+2.2%
TTM-1.2%-3.5%+2.3%
YOY-4.0%-4.2%+0.2%
5Y-0.7%-3.0%+2.3%
10Y-0.7%-4.2%+3.5%
4.3.1.3. Return on Equity

Shows how efficient Bioventus is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Bioventus to the Medical Devices industry mean.
  • -3.2% Return on Equity means Bioventus generated $-0.03 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Bioventus Inc:

  • The MRQ is -3.2%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -6.3%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-3.2%TTM-6.3%+3.1%
TTM-6.3%YOY-18.3%+12.0%
TTM-6.3%5Y-3.7%-2.6%
5Y-3.7%10Y-3.5%-0.2%
Compared to industry (Medical Devices)
PeriodCompanyIndustry (mean)+/- 
MRQ-3.2%-3.9%+0.7%
TTM-6.3%-4.7%-1.6%
YOY-18.3%-5.0%-13.3%
5Y-3.7%-4.6%+0.9%
10Y-3.5%-6.2%+2.7%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Bioventus Inc.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

Measures how efficient Bioventus is operating .

  • Measures how much profit Bioventus makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Bioventus to the Medical Devices industry mean.
  • An Operating Margin of 3.4% means the company generated $0.03  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Bioventus Inc:

  • The MRQ is 3.4%. The company is operating less efficient.
  • The TTM is -2.6%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ3.4%TTM-2.6%+6.0%
TTM-2.6%YOY15.1%-17.7%
TTM-2.6%5Y5.8%-8.4%
5Y5.8%10Y4.7%+1.1%
Compared to industry (Medical Devices)
PeriodCompanyIndustry (mean)+/- 
MRQ3.4%-10.9%+14.3%
TTM-2.6%-21.6%+19.0%
YOY15.1%-14.8%+29.9%
5Y5.8%-16.3%+22.1%
10Y4.7%-14.9%+19.6%
4.3.2.2. Operating Ratio

Measures how efficient Bioventus is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Medical Devices industry mean).
  • An Operation Ratio of 0.94 means that the operating costs are $0.94 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Bioventus Inc:

  • The MRQ is 0.938. The company is less efficient in keeping operating costs low.
  • The TTM is 0.955. The company is less efficient in keeping operating costs low.
Trends
Current periodCompared to+/- 
MRQ0.938TTM0.955-0.018
TTM0.955YOY1.039-0.084
TTM0.9555Y0.979-0.024
5Y0.97910Y0.987-0.008
Compared to industry (Medical Devices)
PeriodCompanyIndustry (mean)+/- 
MRQ0.9381.210-0.272
TTM0.9551.284-0.329
YOY1.0391.319-0.280
5Y0.9791.328-0.349
10Y0.9871.301-0.314
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Bioventus Inc.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Bioventus is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Medical Devices industry mean).
  • A Current Ratio of 1.41 means the company has $1.41 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Bioventus Inc:

  • The MRQ is 1.412. The company is just able to pay all its short-term debts.
  • The TTM is 1.452. The company is just able to pay all its short-term debts.
Trends
Current periodCompared to+/- 
MRQ1.412TTM1.452-0.040
TTM1.452YOY1.369+0.083
TTM1.4525Y1.360+0.092
5Y1.36010Y1.289+0.071
Compared to industry (Medical Devices)
PeriodCompanyIndustry (mean)+/- 
MRQ1.4122.583-1.171
TTM1.4522.696-1.244
YOY1.3692.946-1.577
5Y1.3603.459-2.099
10Y1.2893.470-2.181
4.4.3.2. Quick Ratio

Measures if Bioventus is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Bioventus to the Medical Devices industry mean.
  • A Quick Ratio of 0.78 means the company can pay off $0.78 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Bioventus Inc:

  • The MRQ is 0.780. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 0.823. The company is just not able to pay all its short-term debts with the most liquid assets. -1
Trends
Current periodCompared to+/- 
MRQ0.780TTM0.823-0.043
TTM0.823YOY0.775+0.048
TTM0.8235Y0.934-0.111
5Y0.93410Y0.879+0.055
Compared to industry (Medical Devices)
PeriodCompanyIndustry (mean)+/- 
MRQ0.7801.487-0.707
TTM0.8231.664-0.841
YOY0.7751.905-1.130
5Y0.9342.532-1.598
10Y0.8792.569-1.690
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Bioventus Inc.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much % of Bioventus assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Bioventus to Medical Devices industry mean.
  • A Debt to Asset Ratio of 0.76 means that Bioventus assets are financed with 75.7% credit (debt) and the remaining percentage (100% - 75.7%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Bioventus Inc:

  • The MRQ is 0.757. The company is just able to pay all its debts by selling its assets.
  • The TTM is 0.743. The company is able to pay all its debts by selling its assets. +1
Trends
Current periodCompared to+/- 
MRQ0.757TTM0.743+0.014
TTM0.743YOY0.731+0.012
TTM0.7435Y0.685+0.058
5Y0.68510Y0.651+0.034
Compared to industry (Medical Devices)
PeriodCompanyIndustry (mean)+/- 
MRQ0.7570.401+0.356
TTM0.7430.400+0.343
YOY0.7310.369+0.362
5Y0.6850.430+0.255
10Y0.6510.451+0.200
4.5.4.2. Debt to Equity Ratio

Measures if Bioventus is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Bioventus to the Medical Devices industry mean.
  • A Debt to Equity ratio of 391.7% means that company has $3.92 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Bioventus Inc:

  • The MRQ is 3.917. The company is unable to pay all its debts with equity. -1
  • The TTM is 3.670. The company is unable to pay all its debts with equity. -1
Trends
Current periodCompared to+/- 
MRQ3.917TTM3.670+0.248
TTM3.670YOY3.320+0.349
TTM3.6705Y2.763+0.906
5Y2.76310Y2.585+0.178
Compared to industry (Medical Devices)
PeriodCompanyIndustry (mean)+/- 
MRQ3.9170.579+3.338
TTM3.6700.606+3.064
YOY3.3200.537+2.783
5Y2.7630.640+2.123
10Y2.5850.721+1.864
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Bioventus generates.

  • Above 15 is considered overpriced but always compare Bioventus to the Medical Devices industry mean.
  • A PE ratio of -40.48 means the investor is paying $-40.48 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Bioventus Inc:

  • The EOD is -34.249. Based on the earnings, the company is expensive. -2
  • The MRQ is -40.482. Based on the earnings, the company is expensive. -2
  • The TTM is -19.280. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-34.249MRQ-40.482+6.233
MRQ-40.482TTM-19.280-21.202
TTM-19.280YOY-5.162-14.119
TTM-19.2805Y-49.732+30.452
5Y-49.73210Y-45.211-4.521
Compared to industry (Medical Devices)
PeriodCompanyIndustry (mean)+/- 
EOD-34.249-1.360-32.889
MRQ-40.482-1.535-38.947
TTM-19.280-1.996-17.284
YOY-5.162-2.351-2.811
5Y-49.732-2.413-47.319
10Y-45.211-2.242-42.969
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Bioventus Inc:

  • The EOD is 16.116. Based on how much money comes from the company's main activities, the company is underpriced. +1
  • The MRQ is 19.049. Based on how much money comes from the company's main activities, the company is underpriced. +1
  • The TTM is 5.876. Based on how much money comes from the company's main activities, the company is cheap. +2
Trends
Current periodCompared to+/- 
EOD16.116MRQ19.049-2.933
MRQ19.049TTM5.876+13.173
TTM5.876YOY1.660+4.215
TTM5.8765Y7.487-1.612
5Y7.48710Y6.807+0.681
Compared to industry (Medical Devices)
PeriodCompanyIndustry (mean)+/- 
EOD16.116-1.493+17.609
MRQ19.049-1.969+21.018
TTM5.876-2.299+8.175
YOY1.660-5.177+6.837
5Y7.487-3.825+11.312
10Y6.807-3.051+9.858
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price of Bioventus is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Medical Devices industry mean).
  • A PB ratio of 4.18 means the investor is paying $4.18 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Bioventus Inc:

  • The EOD is 3.537. Based on the equity, the company is fair priced.
  • The MRQ is 4.181. Based on the equity, the company is fair priced.
  • The TTM is 2.323. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD3.537MRQ4.181-0.644
MRQ4.181TTM2.323+1.858
TTM2.323YOY0.639+1.684
TTM2.3235Y1.545+0.777
5Y1.54510Y1.405+0.140
Compared to industry (Medical Devices)
PeriodCompanyIndustry (mean)+/- 
EOD3.5372.059+1.478
MRQ4.1812.340+1.841
TTM2.3232.430-0.107
YOY0.6392.856-2.217
5Y1.5454.282-2.737
10Y1.4054.639-3.234
4.6.2. Total Gains per Share

4.7 Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Bioventus Inc.

4.8.1. Institutions holding Bioventus Inc

Institutions are holding 69.861% of the shares of Bioventus Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-09-30Essex Woodlands Health Ventures19.920144.40841302132400
2024-09-30Juniper Investment Co, LLC10.615934.619369393571055001.5438
2024-09-30Nantahala Capital Management, LLC6.6562.63034350870-6325758-59.2487
2024-09-30BlackRock Inc4.0880.0007267226030087912.6879
2024-09-30Vanguard Group Inc3.17270.0004207390741324124.8841
2024-09-30Morgan Stanley - Brokerage Accounts1.54150.00091007676-39206-3.745
2024-09-30Geode Capital Management, LLC1.43880.0009940496653747.4703
2024-09-30Driehaus Capital Management LLC1.28120.08598375148375140
2024-09-30Royce & Associates, LP1.06730.07586976966976960
2024-09-30State Street Corp1.03490.000367650118921638.8307
2024-09-30Nuveen Asset Management, LLC0.98960.0022646901532302464.491
2024-09-30American Century Companies Inc0.97610.0044638028468867277.172
2024-09-30Ophir Asset Management Pty Ltd0.80190.96395241725241720
2024-09-30Oberweis Asset Management Inc0.78160.312851091413000034.1284
2024-09-30Millennium Management LLC0.66030.0025431594-118441-21.5334
2024-09-30Charles Schwab Investment Management Inc0.59690.000939016210935938.9451
2024-09-30Renaissance Technologies Corp0.59340.007387900-115275-22.9095
2024-09-30Marshall Wace Asset Management Ltd0.58260.00553808274853614.6065
2024-09-30Segall Bryant & Hamill0.5780.06163778243778240
2024-09-30AQR Capital Management LLC0.5610.00613667003667000
Total 57.937883.189837872623-1431500-3.8%

4.9.2. Funds holding Bioventus Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-11-30Vanguard Total Stock Mkt Idx Inv1.5780.00071031474342693.4365
2024-12-31iShares Russell 2000 ETF1.56260.01491021463-3925-0.3828
2024-11-30CREF Stock R11.12710.0069736790551590297.8348
2024-12-31Avantis US Small Cap Value ETF1.10440.05047218976920.096
2024-11-30Vanguard Institutional Extnd Mkt Idx Tr0.97120.006463483738760.6143
2024-09-30Oberweis Micro-Cap0.78161.031551091413000034.1284
2024-09-30Oberweis Micro-Cap Growth0.78161.030551091413000034.1284
2024-11-30Heptagon Driehaus US Micro Cap Eq C$ Acc0.7240.557647326811564632.3375
2024-10-31Fidelity Small Cap Growth0.70890.0814633954633950
2024-09-30Royce Small-Cap Opportunity Invmt0.61960.39284049914049910
2024-10-31Fidelity Small Cap Index0.58990.019538562125760.6725
2024-12-31Invesco Dorsey Wright SmallCap Momt ETF0.51320.34913354456080.1816
2024-11-30FTGF RY US SmCp Opp A USD Dis(A)0.4560.3671298091252539.2557
2024-12-31State St Russell Sm/Mid Cp® Indx NL Cl C0.37380.00572443228130049.8706
2024-12-31iShares Russell 2000 Value ETF0.34990.0195228723-6384-2.7154
2024-11-30Fidelity Extended Market Index0.34950.0063228458-1506-0.6549
2024-12-31Schwab US Small-Cap ETF™0.30310.011419814600
2024-10-31Fidelity Small Cap Growth K60.29540.08041931051931050
2024-12-31Fidelity Enhanced Small Cap ETF0.27170.159817759600
2024-11-30Vanguard Russell 2000 ETF0.26910.015617589746432.7112
Total 13.73064.20718975347+2130129+23.7%
3rd party ad coffee SUPPORTERis ad-free.

5. Financial Statements




5.1. Latest Balance Sheet

Balance Sheet of 2024-09-30. Currency in USD. All numbers in thousands.

Summary
Total Assets769,492
Total Liabilities582,659
Total Stockholder Equity148,738
 As reported
Total Liabilities 582,659
Total Stockholder Equity+ 148,738
Total Assets = 769,492

Assets

Total Assets769,492
Total Current Assets298,688
Long-term Assets470,804
Total Current Assets
Cash And Cash Equivalents 43,074
Net Receivables 121,925
Inventory 90,032
Other Current Assets 43,657
Total Current Assets  (as reported)298,688
Total Current Assets  (calculated)298,688
+/-0
Long-term Assets
Property Plant Equipment 39,204
Goodwill 7,462
Intangible Assets 414,809
Long-term Assets Other 1,933
Long-term Assets  (as reported)470,804
Long-term Assets  (calculated)463,408
+/- 7,396

Liabilities & Shareholders' Equity

Total Current Liabilities211,492
Long-term Liabilities371,167
Total Stockholder Equity148,738
Total Current Liabilities
Short-term Debt 38,566
Accounts payable 16,849
Other Current Liabilities 149,930
Total Current Liabilities  (as reported)211,492
Total Current Liabilities  (calculated)205,345
+/- 6,147
Long-term Liabilities
Long-term Liabilities  (as reported)371,167
Long-term Liabilities  (calculated)0
+/- 371,167
Total Stockholder Equity
Common Stock81
Retained Earnings -354,922
Accumulated Other Comprehensive Income 445
Other Stockholders Equity 503,134
Total Stockholder Equity (as reported)148,738
Total Stockholder Equity (calculated)148,738
+/-0
Other
Cash and Short Term Investments 43,074
Common Stock Shares Outstanding 65,258
Liabilities and Stockholders Equity 769,492
Net Debt 340,513
Net Working Capital 87,196
Short Long Term Debt Total 383,587



5.2. Balance Sheets Structured

Currency in USD. All numbers in thousands.

 Trend2024-09-302024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312016-03-312015-03-31
> Total Assets 
0
486,264
472,407
0
0
479,277
494,466
643,075
646,636
654,790
1,225,862
1,197,137
1,208,776
1,587,220
1,372,649
887,404
836,962
811,104
810,910
794,238
792,173
769,492
769,492792,173794,238810,910811,104836,962887,4041,372,6491,587,2201,208,7761,197,1371,225,862654,790646,636643,075494,466479,27700472,407486,2640
   > Total Current Assets 
0
99,985
183,033
0
0
193,141
211,794
270,721
290,060
246,078
263,103
245,395
277,157
271,082
272,575
308,664
260,638
249,452
267,999
265,903
308,883
298,688
298,688308,883265,903267,999249,452260,638308,664272,575271,082277,157245,395263,103246,078290,060270,721211,794193,14100183,03399,9850
       Cash And Cash Equivalents 
0
6,166
64,520
0
0
72,478
86,839
124,247
136,065
80,917
43,933
27,374
41,001
34,359
31,814
47,102
29,389
26,827
36,964
25,173
31,994
43,074
43,07431,99425,17336,96426,82729,38947,10231,81434,35941,00127,37443,93380,917136,065124,24786,83972,4780064,5206,1660
       Short-term Investments 
0
0
0
0
0
0
19,382
19,382
19,483
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000019,48319,38219,382000000
       Net Receivables 
0
51,109
85,128
0
0
80,813
88,283
89,472
102,029
105,442
124,963
119,288
143,018
132,185
136,645
118,544
119,636
112,899
123,046
125,541
137,305
121,925
121,925137,305125,541123,046112,899119,636118,544136,645132,185143,018119,288124,963105,442102,02989,47288,28380,8130085,12851,1090
       Other Current Assets 
0
5,591
6,059
0
0
5,145
7,552
11,987
15,943
23,154
27,239
34,042
24,060
27,586
18,685
17,192
11,113
10,033
33,312
18,184
51,978
43,657
43,65751,97818,18433,31210,03311,11317,19218,68527,58624,06034,04227,23923,15415,94311,9877,5525,145006,0595,5910
   > Long-term Assets 
0
386,279
289,374
0
0
286,136
282,672
372,354
356,576
408,712
962,759
951,742
931,619
1,316,138
1,100,074
578,740
576,324
561,652
542,911
528,335
483,290
470,804
470,804483,290528,335542,911561,652576,324578,7401,100,0741,316,138931,619951,742962,759408,712356,576372,354282,672286,13600289,374386,2790
       Property Plant Equipment 
0
8,984
19,756
0
0
19,792
21,840
26,144
26,629
27,235
40,171
43,594
43,454
42,947
44,955
52,619
57,100
54,002
49,958
46,994
42,304
39,204
39,20442,30446,99449,95854,00257,10052,61944,95542,94743,45443,59440,17127,23526,62926,14421,84019,7920019,7568,9840
       Goodwill 
0
58,694
49,800
0
0
49,800
49,800
53,529
52,135
52,885
147,623
147,968
143,156
204,557
13,759
7,462
7,462
7,462
7,462
7,462
7,462
7,462
7,4627,4627,4627,4627,4627,4627,46213,759204,557143,156147,968147,62352,88552,13553,52949,80049,8000049,80058,6940
       Long Term Investments 
0
0
0
0
0
19,856
19,382
21,158
19,483
29,317
29,291
28,811
78,486
13,033
2,636
2,620
0
0
0
0
0
0
0000002,6202,63613,03378,48628,81129,29129,31719,48321,15819,38219,85600000
       Intangible Assets 
0
318,141
216,510
0
0
196,688
191,650
271,042
257,848
248,794
695,193
681,369
666,523
1,055,601
1,038,724
516,039
505,223
493,324
482,350
470,668
424,552
414,809
414,809424,552470,668482,350493,324505,223516,0391,038,7241,055,601666,523681,369695,193248,794257,848271,042191,650196,68800216,510318,1410
       Other Assets 
0
0
0
0
0
0
34,343
481
481
50,481
50,481
50,000
0
0
0
0
0
0
0
0
0
0
000000000050,00050,48150,48148148134,343000000
> Total Liabilities 
0
299,962
326,790
0
0
333,938
350,306
422,793
427,272
424,293
692,073
675,219
688,586
1,059,201
1,032,317
647,042
603,621
584,648
589,792
576,806
603,111
582,659
582,659603,111576,806589,792584,648603,621647,0421,032,3171,059,201688,586675,219692,073424,293427,272422,793350,306333,93800326,790299,9620
   > Total Current Liabilities 
0
86,799
89,015
0
0
111,734
122,589
149,027
158,186
160,705
180,859
171,522
198,873
285,719
304,017
196,063
179,104
160,843
175,497
173,321
231,463
211,492
211,492231,463173,321175,497160,843179,104196,063304,017285,719198,873171,522180,859160,705158,186149,027122,589111,7340089,01586,7990
       Short-term Debt 
0
39,290
10,000
0
0
16,250
15,000
15,000
15,000
15,000
18,038
20,292
22,547
31,302
33,056
41,320
11,320
19,584
32,664
40,617
42,395
38,566
38,56642,39540,61732,66419,58411,32041,32033,05631,30222,54720,29218,03815,00015,00015,00015,00016,2500010,00039,2900
       Short Long Term Debt 
0
0
0
0
0
16,250
15,000
15,000
15,000
15,000
18,038
20,292
22,547
31,302
33,056
41,320
11,320
19,584
27,848
35,811
38,566
0
038,56635,81127,84819,58411,32041,32033,05631,30222,54720,29218,03815,00015,00015,00015,00016,25000000
       Accounts payable 
0
9,819
6,440
0
0
8,790
4,422
10,283
9,881
10,897
16,915
22,500
25,735
19,075
37,549
32,828
41,364
17,637
23,038
19,099
24,437
16,849
16,84924,43719,09923,03817,63741,36432,82837,54919,07525,73522,50016,91510,8979,88110,2834,4228,790006,4409,8190
       Other Current Liabilities 
0
7,156
15,619
0
0
18,975
3,926
23,218
35,640
16,379
3,558
128,730
51,699
235,342
233,412
121,915
23,560
21,503
115,046
108,588
159,748
149,930
149,930159,748108,588115,04621,50323,560121,915233,412235,34251,699128,7303,55816,37935,64023,2183,92618,9750015,6197,1560
   > Long-term Liabilities 
0
213,163
237,775
0
0
222,204
227,717
273,766
269,086
263,588
511,214
503,697
489,713
773,482
728,300
450,979
424,517
423,805
414,295
403,485
371,648
371,167
371,167371,648403,485414,295423,805424,517450,979728,300773,482489,713503,697511,214263,588269,086273,766227,717222,20400237,775213,1630
       Long term Debt Total 
0
0
0
0
0
0
0
0
166,084
162,437
0
0
0
0
0
0
0
0
0
0
0
0
000000000000162,437166,08400000000
       Other Liabilities 
0
0
35,297
0
0
31,996
40,231
87,633
103,002
101,151
171,570
139,443
138,280
380,380
0
46,714
37,460
0
0
0
0
0
0000037,46046,7140380,380138,280139,443171,570101,151103,00287,63340,23131,9960035,29700
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
48,410
47,687
133,518
0
0
0
0
0
0
0
0
0
0
0
00000000000133,51847,68748,41000000000
> Total Stockholder Equity
0
186,302
142,982
0
0
143,219
142,241
142,390
141,557
152,503
458,924
449,776
447,981
453,396
316,581
188,511
183,195
177,529
173,591
171,276
150,935
148,738
148,738150,935171,276173,591177,529183,195188,511316,581453,396447,981449,776458,924152,503141,557142,390142,241143,21900142,982186,3020
   Common Stock
0
0
285,147
0
0
285,173
285,173
57
57
57
75
78
80
80
78
79
79
79
79
80
81
81
818180797979797880807875575757285,173285,17300285,14700
   Retained Earnings Total Equity00000-308,137-304,4560-133,376-25,131-17,879-6,602-6,238-5,167-1,0410000000
   Accumulated Other Comprehensive Income 
0
-560
-465
0
0
222
1,607
451
468
204
179
-363
-764
-1,340
-110
413
655
397
794
325
-17
445
445-17325794397655413-110-1,340-764-3631792044684511,60722200-465-5600
   Capital Surplus 
0
0
0
0
0
0
0
142,923
146,199
158,480
465,272
467,940
473,796
478,033
0
492,475
490,598
0
0
0
0
0
00000490,598492,4750478,033473,796467,940465,272158,480146,199142,9230000000
   Treasury Stock0000000000000000000000
   Other Stockholders Equity 
0
284,837
3,309
0
0
2,342
287,092
142,923
146,199
158,480
465,272
467,940
473,796
478,033
481,919
492,475
490,598
492,493
494,254
496,977
500,969
503,134
503,134500,969496,977494,254492,493490,598492,475481,919478,033473,796467,940465,272158,480146,199142,923287,0922,342003,309284,8370



5.3. Balance Sheets

Currency in USD. All numbers in thousands.




5.4. Cash Flows

Currency in USD. All numbers in thousands.




5.5. Income Statements

Currency in USD. All numbers in thousands.


5.6. Latest Income Statement

Income Statement (annual), 2023-12-31. Currency in USD. All numbers in thousands.

Gross Profit (+$)
totalRevenue512,345
Cost of Revenue-184,152
Gross Profit328,193328,193
 
Operating Income (+$)
Gross Profit328,193
Operating Expense-409,918
Operating Income-81,725-81,725
 
Operating Expense (+$)
Research Development13,446
Selling General Administrative300,026
Selling And Marketing Expenses3,853
Operating Expense409,918317,325
 
Net Interest Income (+$)
Interest Income0
Interest Expense-40,676
Other Finance Cost-10,883
Net Interest Income-51,559
 
Pretax Income (+$)
Operating Income-81,725
Net Interest Income-51,559
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-121,111-42,339
EBIT - interestExpense = -121,111
-156,145
-115,554
Interest Expense40,676
Earnings Before Interest and Taxes (EBIT)-80,435-80,435
Earnings Before Interest and Taxes (EBITDA)-23,070
 
After tax Income (+$)
Income Before Tax-121,111
Tax Provision--16,262
Net Income From Continuing Ops-203,757-104,849
Net Income-156,230
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses594,070
Total Other Income/Expenses Net-39,38651,559
 

Technical Analysis of Bioventus
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Bioventus. The general trend of Bioventus is BEARISH with 14.3% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Bioventus's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-14.3%) Bearish trend (14.3%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Bioventus Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 10.27 < 10.92 < 10.94.

The bearish price targets are: 7.3 > 6.2001 > 5.28.

Tweet this
Bioventus Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Bioventus Inc. The current mas is .

The long score for the Moving Averages is 6/14.
The longshort score for the Moving Averages is -2/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Bioventus Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Bioventus Inc. The current macd is -0.48830311.

The long score for the Moving Average Convergence/Divergence (MACD) is 1/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -2/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Bioventus price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Bioventus. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Bioventus price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Bioventus Inc Daily Moving Average Convergence/Divergence (MACD) ChartBioventus Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Bioventus Inc. The current adx is 29.58.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -3/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Bioventus shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX > 25 && ADX trending down: The ADX is above 25 and indicates a strong bearish trend. The ADX is declining, the bearish trend is weakening. Could be a potential reversal to the upside. -2
Bioventus Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Bioventus Inc. The current sar is 11.30.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Bioventus Inc Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Bioventus Inc. The current rsi is 46.58. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 1/13.
The longshort score for the Relative Strength Index (RSI) is -2/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
  • Trending up: The RSI is trending up. +1
Bioventus Inc Daily Relative Strength Index (RSI) ChartBioventus Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Bioventus Inc. The current phase is Correction in bear market.

The long score for the Stochastic Oscillator is 4/6.
The longshort score for the Stochastic Oscillator is 4/(-6 +6).

  • STOCH > 50: The STOCH %K is above 50. There are more buyers than sellers. +1
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Bioventus price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
Bioventus Inc Daily Stochastic Oscillator ChartBioventus Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Bioventus Inc. The current cci is -30.57609455.

Bioventus Inc Daily Commodity Channel Index (CCI) ChartBioventus Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Bioventus Inc. The current cmo is 2.93590144.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
Bioventus Inc Daily Chande Momentum Oscillator (CMO) ChartBioventus Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Bioventus Inc. The current willr is -41.99134199.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Bioventus is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Bioventus Inc Daily Williams %R ChartBioventus Inc Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Bioventus Inc.

Bioventus Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Bioventus Inc. The current atr is 0.55093421.

Bioventus Inc Daily Average True Range (ATR) ChartBioventus Inc Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Bioventus Inc. The current obv is 90,006,234.

Bioventus Inc Daily On-Balance Volume (OBV) ChartBioventus Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Bioventus Inc. The current mfi is 25.73.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Bioventus Inc Daily Money Flow Index (MFI) ChartBioventus Inc Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Bioventus Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2024-08-26STOCH SHORT EXITThe %K line crosses above the %D line.
2024-08-27RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-08-29STOCH SHORT EXITThe %K line crosses above the %D line.
2024-09-03RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2024-09-04STOCH LONG EXITThe %K line crosses below the %D line.
2024-09-06MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-09-09SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-09-10RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-09-11MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-09-12CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-09-13STOCH LONG EXITThe %K line crosses below the %D line.
2024-09-17STOCH SHORT EXITThe %K line crosses above the %D line.
2024-09-18BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-09-19STOCH LONG EXITThe %K line crosses below the %D line.
2024-09-20STOCH SHORT EXITThe %K line crosses above the %D line.
2024-09-23RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-09-25MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-09-26SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-09-27SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-09-30STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-10-01STOCH LONG EXITThe %K line crosses below the %D line.
2024-10-07SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-10-08STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-10-10STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-10-11STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-10-14SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-10-15MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-10-17STOCH LONG EXITThe %K line crosses below the %D line.
2024-10-18STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-10-21STOCH LONG EXITThe %K line crosses below the %D line.
2024-10-22STOCH SHORT EXITThe %K line crosses above the %D line.
2024-10-24STOCH LONG EXITThe %K line crosses below the %D line.
2024-10-29STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-10-30CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-11-01STOCH LONG EXITThe %K line crosses below the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-11-05MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-11-06BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-11-08STOCH SHORT EXITThe %K line crosses above the %D line.
2024-11-11CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-11-12STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-11-13CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-11-15STOCH SHORT EXITThe %K line crosses above the %D line.
2024-11-20STOCH LONG EXITThe %K line crosses below the %D line.
2024-11-21STOCH SHORT EXITThe %K line crosses above the %D line.
2024-11-22WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-11-25STOCH LONG EXITThe %K line crosses below the %D line.
2024-11-26MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-11-27DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-12-02DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-12-03CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-12-04MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-12-05STOCH SHORT EXITThe %K line crosses above the %D line.
2024-12-09STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-12-10STOCH SHORT EXITThe %K line crosses above the %D line.
2024-12-12STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-12-13CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-12-16STOCH SHORT EXITThe %K line crosses above the %D line.
2024-12-18STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-12-19STOCH SHORT EXITThe %K line crosses above the %D line.
2024-12-27STOCH LONG EXITThe %K line crosses below the %D line.
2024-12-30CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-01-02STOCH SHORT EXITThe %K line crosses above the %D line.
2025-01-03STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-01-06CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-01-07SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2025-01-08RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2025-01-13STOCH SHORT EXITThe %K line crosses above the %D line.
2025-01-14STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-01-15RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-01-16CMO LONG ENTRY SHORT CLOSEZero line crossover to upside

6.3. Candlestick Patterns

Bioventus Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Bioventus Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5046.575
Ma 20Greater thanMa 5010.205
Ma 50Greater thanMa 10011.063
Ma 100Greater thanMa 20011.321
OpenGreater thanClose9.740
Total1/5 (20.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Bioventus with someone you think should read this too:
  • Are you bullish or bearish on Bioventus? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Bioventus? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Bioventus Inc

I send you an email if I find something interesting about Bioventus Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Bioventus Inc.

Receive notifications about Bioventus Inc in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.